Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis

Area of Science:

• Cardiovascular Genetics
• Lipid Metabolism
• Personalized Medicine

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder characterized by high LDL cholesterol.
• Some FH patients are unresponsive to standard therapies and require LDL apheresis.
• The genetic basis and phenotypic presentation of FH can be complex.

Purpose of the Study:

• To investigate the genotype-phenotype correlation in patients with dyslipidemia undergoing LDL apheresis.
• To identify specific genetic mutations (LDLR, PCSK9, APOB) in patients receiving apheresis.
• To assess the impact of genetic mutations on lipid profiles and atherogenic risk.

Main Methods:

• Genetic analysis of LDLR, APOB, and PCSK9 genes in seven patients undergoing LDL apheresis.
• Collection and analysis of plasma and serum samples pre- and post-apheresis.
• Measurement of lipid concentrations, Lp(a) cholesterol, and lipoprotein particle concentrations via NMR.

Main Results:

• Four out of seven patients had detectable LDLR mutations; three presented with xanthomas.
• All patients showed similar reductions in LDL-cholesterol (LDL-C), apolipoprotein B, and LDL particles (LDL-P) post-apheresis.
• Patients with LDLR mutations exhibited a more pro-atherogenic profile pre-apheresis compared to those without identified mutations.

Conclusions:

• Not all clinically diagnosed FH patients requiring apheresis have identifiable genetic mutations.
• LDLR mutations are associated with a more pro-atherogenic phenotype in this cohort.
• Genetic stratification of apheresis patients may help optimize lipid-lowering therapy.